Asset Planning Inc Makes New Investment in Exact Sciences Co. (NASDAQ:EXAS)

Asset Planning Inc bought a new position in shares of Exact Sciences Co. (NASDAQ:EXAS) during the 4th quarter, HoldingsChannel reports. The firm bought 703 shares of the medical research company’s stock, valued at approximately $40,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in shares of Exact Sciences by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company’s stock valued at $211,104,000 after buying an additional 7,873 shares in the last quarter. Champlain Investment Partners LLC boosted its holdings in shares of Exact Sciences by 10.9% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company’s stock valued at $169,924,000 after buying an additional 245,980 shares in the last quarter. Bellevue Group AG boosted its holdings in shares of Exact Sciences by 25.1% in the 3rd quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock valued at $98,738,000 after buying an additional 290,585 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Exact Sciences by 3.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock valued at $88,017,000 after buying an additional 45,015 shares in the last quarter. Finally, Groupama Asset Managment bought a new stake in shares of Exact Sciences in the 3rd quarter valued at about $821,000. 88.82% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. TD Cowen raised their price target on shares of Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Jefferies Financial Group increased their price objective on shares of Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Craig Hallum decreased their price objective on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Citigroup decreased their price objective on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, Piper Sandler decreased their price objective on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $72.76.

Exact Sciences Price Performance

NASDAQ:EXAS opened at $49.31 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The firm has a market cap of $9.13 billion, a price-to-earnings ratio of -42.14 and a beta of 1.24. The company has a 50 day moving average price of $56.15 and a 200-day moving average price of $60.09. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.